Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Histologic remission fails to be related to UC relapse
Key clinical point: Histologic remission had no apparent impact on time to relapse in ulcerative colitis patients with endoscopic remission.
Major finding: The median times to relapse were 2.92 years, 3.0 years, and 4.0 years in patients with normal histology, inactive colitis, and active colitis, respectively.
Study details: The data come from a retrospective, observational study of 269 adults with ulcerative colitis with endoscopic remission.
Disclosures: The study received no outside funding. Lead author Dr. Narula disclosed honoraria from Janssen, AbbVie, Takeda, Pfizer, Merck, and Ferring. Dr. Sakuraba had no financial conflicts to disclose.
Narula N et al. Aliment Pharmacol Ther. 2020 Oct 20. doi: 10.1111/apt.16147.